Article
Medicine, General & Internal
Ian M. McElree, Ryan L. Steinberg, Sarah L. Mott, Michael A. O'Donnell, Vignesh T. Packiam
Summary: Due to the shortage of BCG, gemcitabine and docetaxel have been used as a first-line therapy for high-risk NMIBC. This study compared the outcomes of patients treated with gemcitabine and docetaxel vs BCG and found that gemcitabine and docetaxel therapy was associated with better high-grade recurrence-free survival and treatment discontinuation.
Article
Oncology
Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F. Correa, Diana E. Magee
Summary: This study evaluated the cost effectiveness of BCG compared to sequential gemcitabine-docetaxel in high-risk NMIBC patients. The results showed that gemcitabine-docetaxel had similar effectiveness but lower cost than BCG, making it a potential alternative as a first-line intravesical therapy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Phani T. Chevuru, Ian M. McElree, Sarah L. Mott, Ryan L. Steinberg, Michael A. O'Donnell, Vignesh T. Packiam
Summary: Intravesical gemcitabine and docetaxel (Gem/Doce) has been proven as a safe and effective salvage treatment for recurrent non-muscle-invasive bladder cancer (NMIBC) since 2015. However, the long-term outcomes of this treatment have not been extensively studied. This article reports on a large cohort of patients who received intravesical Gem/Doce after failure of bacillus Calmette-Guérin (BCG) therapy, with extended follow-up. The study showed a 5-year bladder preservation rate of 75% and a 5-year cancer-specific survival rate of 91%, suggesting the efficacy of Gem/Doce as a salvage treatment for high-risk NMIBC after BCG failure.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Urology & Nephrology
Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg, Sarah L. Mott, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell
Summary: Valrubicin and docetaxel have shown to be an effective rescue therapy for recurrent non-muscle-invasive bladder cancer.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Ian M. McElree, Ryan L. Steinberg, Alex C. Martin, Jordan Richards, Sarah L. Mott, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell, Vignesh T. Packiam
Summary: This study retrospectively analyzed the outcomes of patients with high-risk BCG-naive NMIBC treated with Gem/Doce and found that Gem/Doce was an effective and well-tolerated therapy.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Francesco Del Giudice, Rocco Simone Flammia, Benjamin I. Chung, Marco Moschini, Benjamin Pradere, Andrea Mari, Francesco Soria, Simone Albisinni, Wojciech Krajewski, Tomasz Szydelko, Ekaterina Laukhtina, David D'Andrea, Andrea Gallioli, Laura S. Mertens, Martina Maggi, Alessandro Sciarra, Stefano Salciccia, Matteo Ferro, Carlo Maria Scornajenghi, Vincenzo Asero, Susanna Cattarino, Mario De Angelis, Giovanni E. Cacciamani, Riccardo Autorino, Savio Domenico Pandolfo, Ugo Giovanni Falagario, Nicola D'Altilia, Vito Mancini, Marco Chirico, Francesco Cinelli, Carlo Bettocchi, Luigi Cormio, Giuseppe Carrieri, Ettore De Berardinis, Gian Maria Busetto
Summary: In this study, the efficacy of two different BCG strains (RIVM and TICE) in the treatment of high-risk non-muscle invasive bladder cancer was compared. The results showed that when routine secondary resection followed by a maintenance BCG schedule was performed, the TICE strain was superior to the RIVM strain in terms of RFS outcomes. However, no significant differences were found in PFS and CSS outcomes.
Review
Medicine, General & Internal
Mi Ah Han, Philipp Maisch, Jae Hung Jung, Jun Eul Hwang, Vikram Narayan, Anne Cleves, Eu Chang Hwang, Philipp Dahm
Summary: This study assessed the comparative effectiveness and toxicity of intravesical gemcitabine for NMIBC and found that gemcitabine may have a more favorable impact on recurrence and progression-free survival compared to mitomycin and BCG, but uncertainty remains regarding major adverse events. Therefore, better quality studies are needed to confirm these results.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Oncology
Ryan L. Steinberg, Vignesh T. Packiam, Lewis J. Thomas, Nathan Brooks, Andrew Vitale, Sarah L. Mott, Trafford Crump, Jonathan Wang, William C. DeWolf, Donald L. Lamm, Max Kates, M. Eric Hyndman, Ashish M. Kamat, Trinity J. Bivalacqua, Kenneth G. Nepple, Michael A. O'Donnell
Summary: Repeat BCG induction is still an option for some select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated. The study aimed to compare the efficacy of BCG plus interferon a-2b (BCG/IFN) and Gem/Doce in patients with recurrent NMIBC after a single prior BCG course, showing similar oncologic outcomes for both treatment options.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Pharmacology & Pharmacy
Mohamad Abou Chakra, Vignesh T. Packiam, Michael A. O'Donnell
Summary: This article discusses the treatment regimen, safety, and efficacy of single-agent intravesical gemcitabine in different disease states of NMIBC. The study results show that single-agent gemcitabine is more effective for patients with BCG failure or without muscle invasion, but less effective for patients with CIS, high-risk disease, and extensive BCG failure.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Oncology
Vassili Anastay, Michael Baboudjian, Alexandra Masson-Lecomte, Cedric Lebacle, Alexandre Chamouni, Jacques Irani, Xavier Tillou, Thibaut Waeckel, Arnaud Monges, Celine Duperron, Gwenaelle Gravis, Jochen Walz, Eric Lechevallier, Geraldine Pignot
Summary: Intravesical instillations of BCG are the standard treatment for high-risk non-muscle-invasive bladder cancer. Radical cystectomy is recommended for BCG failure cases. Bladder-sparing techniques, including Hyperthermic IntraVesical Chemotherapy (HIVEC), are being evaluated as alternatives. This multicentric retrospective study found no increased recurrence or progression rates in BCG-failed patients treated with HIVEC, encouraging further evaluation of HIVEC regardless of the presence of CIS in non-muscle-invasive bladder carcinoma.
Article
Oncology
Wei Shen Tan, Ian M. McElree, Facundo Davaro, Ryan L. Steinberg, Kelly Bree, Neema Navai, Colin P. Dinney, Michael A. O'Donnell, Roger Li, Ashish M. Kamat, Vignesh T. Packiam
Summary: We evaluated the outcomes of two different treatments for intermediate-risk non-muscle-invasive bladder cancer and found that the chemotherapy combination of docetaxel and gemcitabine is as effective as the traditional BCG treatment.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Review
Urology & Nephrology
Tatsushi Kawada, Takafumi Yanagisawa, Motoo Araki, Benjamin Pradere, Shahrokh. F. F. Shariat
Summary: The study reviewed the efficacy and safety of intravesical gemcitabine (GEM) and docetaxel (DOCE) in the treatment of high-risk nonmuscle invasive bladder cancer (HR-NMIBC) patients who have not been treated with Bacillus Calmette-Guerin (BCG) or are unresponsive to BCG. The results showed that the combination therapy had high recurrence-free survival rates and was well tolerated. However, further comparative studies with BCG are needed.
CURRENT OPINION IN UROLOGY
(2023)
Article
Oncology
Tianwei Wang, Xiaobing Niu, Bing Zhong
Summary: The molecular subtypes of non-muscle invasive bladder cancer based on immunohistochemical results are independent risk factors for the prognosis, with different therapeutic methods recommended for different subtypes. Gemcitabine showed reduced recurrence compared with anthracycline in basal-like subtypes, but no difference in progression.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Medicine, General & Internal
Fouad Nahhat, Modar Doyya, Hazem Ksiri
Summary: This case report highlights the role of gemcitabine as a bladder sparing treatment in BCG-failure patients, with a 57-year-old man with BCG-refractory bladder cancer showing a complete response to intravesical gemcitabine.
CLINICAL CASE REPORTS
(2022)
Article
Oncology
Rodolfo Hurle, Roberto Contieri, Paolo Casale, Emanuela Morenghi, Alberto Saita, Nicolomaria Buffi, Giovanni Lughezzani, Piergiuseppe Colombo, Nicola Frego, Vittorio Fasulo, Marco Paciotti, Giorgio Guazzoni, Massimo Lazzeri
Summary: The study reported mid-term results of intravesical gemcitabine in non-muscle-invasive bladder cancer patients, showing a disease-free survival rate of 32.69% at 3 years. The most common adverse events were urinary symptoms and fatigue.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
